Priovant Therapeutics
Pre-clinicalPriovant Therapeutics is a clinical-stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $285M
About
Priovant Therapeutics is a clinical-stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.
Small Molecules
Funding History
2Total raised:$285M
Series B$235MOct 15, 2022
Series A$50MOct 15, 2021